On January 13, 2026, PLUS Therapeutics, Inc. entered into an agreement to sell 39,473,684 shares and warrants at $0.38 per share, raising approximately $13.3 million after costs, with the offering closing on January 15, 2026. This is a significant event as it impacts the company's capital structure and funding plans.